Upcoming Webinar:Join us for Sustainability 100+ Dialogues 2021-Maharashtra Roundtable& know how the state is progressing on climate action

Buy Sun Pharmaceutical Industries: target of Rs 810: Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 810 in its research report dated May 27, 2021.

June 10, 2021 / 11:33 AM IST
  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Sun Pharmaceutical Industries

Q4FY21 numbers were strong with Sun Pharma reporting higher-than-expected earnings. India business growth is expected to backed by new product launches, improving the field force’s productivity and expected traction in existing business. In FY21 Sun Pharma has launched 31 products, which would gather pace going ahead. The outlook for the US business has improved, following a pick-up in the lucrative specialty business with the management eyeing market share gains. The management sees uncertainties to stay due to Covid, however it stays focused on growing the performance across segments as the long term growth levers are intact.


We retain Buy recommendation on the stock with a revised PT of Rs. 810.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 31, 2021 01:38 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark